Ambuja Neotia Healthcare Announces Investment to Set Up 120-Bed Woman and Child Hospital in Howrah

Date:

Share post:

Ambuja Neotia Healthcare Venture Ltd (ANHVL) has unveiled plans to establish a 120-bed specialized woman and child care hospital in Howrah, West Bengal, committing an investment of approximately ₹150 crore. Slated to become operational by April 2029, the facility will function under the group’s flagship brand, Neotia Bhagirathi Woman and Child Care Centre.

​The new unit aims to address the significant demand for dedicated maternal, neonatal, and pediatric healthcare services in Howrah, identified as one of the region’s fastest-growing corridors. By bringing advanced clinical expertise and modern infrastructure closer to the local community, the hospital seeks to deliver compassionate, high-quality medical care tailored to families in the area.

​Highlighting the group’s vision, Parthiv Neotia, Managing Director of Ambuja Neotia, emphasized that healthcare is fundamentally a trust-driven business. The Howrah development is structured to build on that foundation by bridging the critical gap in super-specialty mother-and-child care across the twin-city region.

​This project marks a vital milestone in ANHVL’s larger strategic vision for Eastern India. The company has embarked on a ₹2,200-crore regional expansion plan over the next four to five years. Under this aggressive roadmap, the group intends to add approximately 1,800 beds across various upcoming projects, significantly expanding its footprint and scaling total network capacity to 2,500 beds.

​Through this phased investment, Ambuja Neotia Healthcare reaffirms its commitment to strengthening the healthcare ecosystem in Eastern India with world-class, patient-centric clinical infrastructure.

Written by: Pragna Biswas

Graphics by: Pramit Hazra

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related articles

AbbVie Submits Regulatory Application to EMA for Subcutaneous Induction of SKYRIZI®️ in Crohn’s Disease

AbbVie announced the submission of a regulatory application to the European Medicines Agency (EMA) seeking approval for SKYRIZI®...

FDA Approves Takeda’s First-in-Class Therapy MIMRYLO for Polycythemia Vera Following Robust Phase 3 Results

Takeda announced that the U.S. Food and Drug Administration (FDA) has approved MIMRYLO, a first-in-class therapy indicated for...

Maharashtra FDA Withdraws Drug License Cancellation Order for Cipla C&F Unit Following Bombay High Court Rebuke

In a major regulatory development, the Maharashtra Food and Drug Administration (FDA) has withdrawn its order cancelingthe drug sale...

Orsini Partners with Priovant to Support Access to New Dermatomyositis Therapy LISRAYA

Orsini, a specialty pharmacy known for its work in rare disease care, has been named a specialty pharmacy...